(R)-baclofen是一种γ-氨基丁酸衍生物,主要用于治疗痉挛。是选择性GABAB受体激动剂。
(R)-baclofen is a derivative of gamma-aminobutyric acid primarily used to treat spasticity.
动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数 | |
例如,已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法:将88 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到该药物用于大鼠的等效剂量44 mg/kg。
[1] Falch E, et al. J Neurochem, 1986, 47(3), 898-903.
分子式 C10H12ClNO2 |
分子量 213.66 |
CAS号 69308-37-8 |
储存方式 ﹣20 ℃冷藏长期储存。冰袋运输 |
溶剂(常温) |
DMSO <1 mg/mL |
Water 10 mg/mL |
Ethanol <1 mg/mL |
体内溶解度
NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
NCT01172509 | Autism | Drug: R-baclofen | Gonzalez-Heydrich, Joseph, M.D.|Boston Children Hospital|Seaside Therapeutics, Inc. | Phase 1 | 2010-10-01 | 2015-08-20 |
NCT03058237 | Healthy Volunteers | Drug: Arbaclofen Placarbil SR|Drug: Arbaclofen Placarbil MR Prototype A|Drug: Arbaclofen Placarbil MR Prototype B|Drug: Arbaclofen Placarbil IR | Indivior Inc. | Phase 1 | 2017-01-23 | 2017-02-15 |
NCT01064973 | Autism Spectrum Disorders | Drug: arbaclofen | Seaside Therapeutics, Inc. | Phase 2 | 2010-02-01 | 2012-12-19 |
NCT01013480 | Fragile X Syndrome | Drug: Arbaclofen | Seaside Therapeutics, Inc. | Phase 2 | 2009-11-01 | 2012-12-19 |
NCT01821560 | Nicotine Dependence | Drug: Baclofen|Drug: placebo | University of Pennsylvania|National Institute on Drug Abuse (NIDA)|National Institutes of Health (NIH) | Phase 2 | 2013-03-01 | 2016-08-30 |
NCT01288716 | Autism Spectrum Disorders | Drug: Arbaclofen | Seaside Therapeutics, Inc. | Phase 2 | 2011-05-01 | 2013-07-30 |
NCT00218166 | Cocaine-Related Disorders | Drug: GABA Agonists | National Institute on Drug Abuse (NIDA) | Phase 2 | 2001-08-01 | 2017-01-10 |
NCT01386255 | Cerebral Palsy|GERD | Drug: Baclofen|Drug: placebo | Boston Children Hospital|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 4 | 2009-04-01 | 2011-06-29 |
NCT02011516 | Marijuana Dependence | Drug: Baclofen|Behavioral: Psychosocial|Drug: Placebo | University of Pennsylvania|Pennsylvania Department of Health | Phase 2 | 2013-12-01 | 2015-12-23 |
NCT01325220 | Fragile X Syndrome | Drug: arbaclofen|Drug: arbaclofen|Drug: arbaclofen|Drug: Placebo | Seaside Therapeutics, Inc. | Phase 3 | 2011-06-01 | 2013-07-30 |
NCT00320047 | Eating Disorders|Bulimia Nervosa | Drug: Baclofen | New York State Psychiatric Institute|National Institute of Mental Health (NIMH) | 2005-04-01 | 2013-08-08 | |
NCT01520545 | Severe Spasticity | Drug: Gablofen 3 mg/mL (baclofen injection) | Mallinckrodt | Phase 3 | 2012-12-01 | 2016-10-18 |
NCT02462317 | Muscle Spasticity | Drug: botulinum A toxin|Drug: Baclofen|Drug: Placebo toxin|Drug: placebo baclofen | University Hospital, Toulouse|Merz Pharmaceuticals GmbH | Phase 4 | 2015-04-01 | 2016-12-13 |
NCT02511886 | Alcohol Use Disorder | Drug: Arbaclofen Placarbil|Drug: Placebo | Indivior Inc. | Phase 2 | 2015-09-01 | 2017-01-19 |
注:以上所有数据均来自公开文献,并不保证对所有实验均有效,数据仅供参考。
相关化合物库
使用AMQUAR产品发表文献后请联系我们